Comparison of Ocrelizumab and Rituximab over Two Years of Treatment for Multiple Sclerosis

被引：0
|
作者：
Vollmer, B. [1 ]
Nair, K. [2 ]
Sillau, S. [3 ]
Corboy, J. R. [3 ]
Alvarez, E. [3 ]
机构：
[1] Univ Colorado, Neurol, Denver, CO USA
[2] Univ Colorado, Pharm, Aurora, CO USA
[3] Univ Colorado, Neurol, Aurora, CO USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P159
引用
收藏
页码：92 / 93
页数：2
相关论文
共 50 条
  • [1] Ocrelizumab real-world safety and effectiveness in the two years of treatment in multiple sclerosis
    Vollmer, B.
    Declusin, A.
    Nair, K.
    Sillau, S.
    Corboy, J.
    Vollmer, T.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 294 - 295
  • [2] Ocrelizumab for the treatment of multiple sclerosis
    Bigaut, Kevin
    De Seze, Jerome
    Collongues, Nicolas
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (02) : 97 - 108
  • [3] Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No
    Wallin, Mitchell T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (09) : 1159 - 1161
  • [4] Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
    Roos, Izanne
    Hughes, Stella
    McDonnell, Gavin
    Malpas, Charles B.
    Sharmin, Sifat
    Boz, Cavit
    Alroughani, Raed
    Ozakbas, Serkan
    Buzzard, Katherine
    Skibina, Olga
    van der Walt, Anneke
    Butzkueven, Helmut
    Lechner-Scott, Jeannette
    Kuhle, Jens
    Terzi, Murat
    Laureys, Guy
    Van Hijfte, Liesbeth
    John, Nevin
    Grammond, Pierre
    Grand'Maison, Francois
    Soysal, Aysun
    Jensen, Ana Voldsgaard
    Rasmussen, Peter Vestergaard
    Svendsen, Kristina Bacher
    Barzinji, Ismael
    Nielsen, Helle Hvilsted
    Sejbaek, Tobias
    Prakash, Sivagini
    Stilund, Morten Leif Munding
    Weglewski, Arkadiusz
    Issa, Nadia Mubder
    Kant, Matthias
    Sellebjerg, Finn
    Gray, Orla
    Magyari, Melinda
    Kalincik, Tomas
    MSBase Study Grp
    Danish MS Registry Study Grp
    JAMA NEUROLOGY, 2023, 80 (08) : 789 - 797
  • [5] Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes
    Piehl, Fredrik
    Hillert, Jan
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (09) : 1157 - 1159
  • [6] Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (09) : 1161 - 1162
  • [7] The efficacy of ocrelizumab versus rituximab in treating patients with multiple sclerosis
    Shalaby, Nevin
    Abdul-Rahman, Ahmed
    Hegazy, Mohamed
    Merghany, Nahla
    Mounir, Nesma
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 600 - 601
  • [8] Ocrelizumab two-year real-world safety and effectiveness over in the treatment of multiple sclerosis
    Vollmer, Brandi
    Ijadi, Nassim
    Declusin, Anthony
    Nair, Kavita
    Sillau, Stefan
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2021, 96 (15)
  • [9] Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis
    Graille-Avy, Lisa
    Boutiere, Clemence
    Rigollet, Camille
    Perriguey, Marine
    Rico, Audrey
    Demortiere, Sarah
    Durozard, Pierre
    Hilezian, Frederic
    Vely, Frederic
    Bertault-Peres, Pierre
    Pelletier, Jean
    Maarouf, Adil
    Audoin, Bertrand
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (03): : e200231
  • [10] Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment
    Ozakbas, S.
    Ozcelik, S.
    Kaya, E.
    Ozdogar, T.
    Sagici, O.
    Baba, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (2_SUPPL) : 9 - 9
12345